CA3254546A1 - COMPOSITIONS CONTAINING ATICAPRANT - Google Patents

COMPOSITIONS CONTAINING ATICAPRANT

Info

Publication number
CA3254546A1
CA3254546A1 CA3254546A CA3254546A CA3254546A1 CA 3254546 A1 CA3254546 A1 CA 3254546A1 CA 3254546 A CA3254546 A CA 3254546A CA 3254546 A CA3254546 A CA 3254546A CA 3254546 A1 CA3254546 A1 CA 3254546A1
Authority
CA
Canada
Prior art keywords
aticaprant
treatment
weight
pharmaceutical composition
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3254546A
Other languages
English (en)
French (fr)
Inventor
Nicolaas Martha Felix Goyvaerts
Mark Schmidt
Vanina Popova
Adam J. SAVITZ
Rama Melkote
Wayne C. Drevets
MD Srihari GOPAL
Darrel Pemberton
Chakradhar Lagishetty
Iva Kezic
Mahesh N. Samtani
Tom Huybrechts
Geert Van Der Avoort
Matthieu Ravelingien
Laura Martinez Marcos
Tatiana MARCOZZI
Katarina Jokicevic
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CA3254546A1 publication Critical patent/CA3254546A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3254546A 2022-03-07 2023-03-06 COMPOSITIONS CONTAINING ATICAPRANT Pending CA3254546A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317471P 2022-03-07 2022-03-07
US63/317,471 2022-03-07
PCT/IB2023/052097 WO2023170554A1 (en) 2022-03-07 2023-03-06 Compositions comprising aticaprant

Publications (1)

Publication Number Publication Date
CA3254546A1 true CA3254546A1 (en) 2023-09-14

Family

ID=85980700

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3254546A Pending CA3254546A1 (en) 2022-03-07 2023-03-06 COMPOSITIONS CONTAINING ATICAPRANT

Country Status (16)

Country Link
US (3) US20230277500A1 (https=)
EP (1) EP4489730B1 (https=)
JP (1) JP2025508069A (https=)
KR (1) KR20240152410A (https=)
CN (1) CN119156202A (https=)
AU (1) AU2023231767A1 (https=)
CA (1) CA3254546A1 (https=)
CL (1) CL2024002648A1 (https=)
CO (1) CO2024012454A2 (https=)
ES (1) ES3064226T3 (https=)
IL (1) IL315415A (https=)
JO (1) JOP20240196A1 (https=)
MX (1) MX2024010977A (https=)
TW (1) TW202400135A (https=)
UY (1) UY40173A (https=)
WO (1) WO2023170554A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
WO2000069858A1 (en) 1999-05-12 2000-11-23 F. Hoffmann-La Roche Ag Imidazodiazepine derivative
JP2004510789A (ja) 2000-10-05 2004-04-08 モーラー，ハンス 選択的抗不安治療薬
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
US7396943B2 (en) 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
CN1756746A (zh) 2003-03-07 2006-04-05 伊莱利利公司 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
BRPI0417156A (pt) 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
EP1727788B1 (en) 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
JP2007529523A (ja) 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
CA2557794A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
WO2009094260A1 (en) 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
BR112013002846A2 (pt) 2010-08-05 2016-06-07 Conrig Pharma Aps derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
EP2773352B1 (en) 2011-12-09 2017-06-28 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
MX368870B (es) 2013-12-20 2019-10-21 H Lundbeck As Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
US10377698B2 (en) 2015-03-30 2019-08-13 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
US10709685B2 (en) 2015-05-28 2020-07-14 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
SI3881833T1 (sl) * 2015-06-30 2024-03-29 Genentech, Inc., Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet
WO2017218518A1 (en) 2016-06-13 2017-12-21 Board Of Regents Of The University Of Texas System Pharmaceutical compositions and methods for treatment of pain
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
JP7048572B6 (ja) 2016-09-16 2023-12-20 リサーチ トライアングル インスティテュート テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
ES2926533T3 (es) 2017-03-17 2022-10-26 Scripps Research Inst Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos
PH12018000077B1 (en) * 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
WO2019183556A1 (en) 2018-03-23 2019-09-26 University Of Kansas Cyclic tetrapeptide analogs
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
JP2022505676A (ja) 2018-10-23 2022-01-14 ブラックソーン セラピューティクス インコーポレイテッド 患者のスクリーニング、診断、及び層別化のためのシステム及び方法
US20200171025A1 (en) * 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2022268720A1 (en) * 2021-05-04 2023-12-21 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170547A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Also Published As

Publication number Publication date
MX2024010977A (es) 2024-12-06
KR20240152410A (ko) 2024-10-21
IL315415A (en) 2024-11-01
US12201610B2 (en) 2025-01-21
US20240269110A1 (en) 2024-08-15
CO2024012454A2 (es) 2024-09-30
ES3064226T3 (en) 2026-04-23
UY40173A (es) 2023-09-29
AU2023231767A1 (en) 2024-10-24
CL2024002648A1 (es) 2025-01-24
TW202400135A (zh) 2024-01-01
US20230277500A1 (en) 2023-09-07
CN119156202A (zh) 2024-12-17
EP4489730B1 (en) 2026-01-21
WO2023170554A1 (en) 2023-09-14
JP2025508069A (ja) 2025-03-21
JOP20240196A1 (ar) 2024-09-05
EP4489730C0 (en) 2026-01-21
US20250228819A1 (en) 2025-07-17
EP4489730A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
US12201610B2 (en) Compositions comprising aticaprant
US11980596B2 (en) Delivery of esketamine for the treatment of depression
US11266627B1 (en) Compositions and methods for the treatment of depression
CA3219079A1 (en) Compositions and methods for the treatment of depression
US12419859B2 (en) Compositions and methods for the treatment of depression
WO2023170547A1 (en) Pure forms of crystalline aticaprant
CA3254365A1 (en) POLYMORPHIC FORMS OF ATICAPRANT INTENDED FOR USE IN THE TREATMENT OF MAJOR DEPRESSION
US20250221960A1 (en) Compositions and methods for the treatment of depression
US20250177350A1 (en) Compositions and methods for the treatment of depression
US20240238245A1 (en) Compositions and methods for the treatment of depression
WO2025245066A1 (en) Compositions and methods for affecting weight loss, weight management, sexual disorders, well-being, self-esteem, and/or self-confidence
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
CA3247733A1 (en) Compositions and methods of treating depression
US20250205200A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression
CN121969364A (zh) 用于在治疗重性抑郁障碍中使用的包含阿替卡普兰的组合物
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240905

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250204

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250206

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250206

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250819

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260203